Ghaziabad Online

Eosinophilic Esophagitis Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

 Breaking News
  • No posts were found

Eosinophilic Esophagitis Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

September 27
22:11 2022
Eosinophilic Esophagitis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

DelveInsight’s, “Eosinophilic Esophagitis Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Eosinophilic Esophagitis pipeline landscape

 

DelveInsight’s ‘Eosinophilic Esophagitis Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Eosinophilic esophagitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Eosinophilic esophagitis pipeline domain.

 

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report

  • DelveInsight’s Eosinophilic esophagitis pipeline report depicts a robust space with 15+ active players working to develop 15 + pipeline therapies for Eosinophilic esophagitis treatment. 
  • Leading Eosinophilic esophagitis companies such as Sanofi/Regeneron, AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, DBV Technologies, Celldex Therapeutics, NexEos Bio, Aqilion,  Quorum Innovations, Serpin Pharma, RAPT Therapeutics and others are evaluating novel Eosinophilic esophagitis treatment drugs candidate to improve the treatment landscape.
  • Key Eosinophilic esophagitis pipeline therapies in various stages of development includes Dupilumab, Benralizumab, CC-93538, APT-1011, AK002, ESO-101, Etrasimod, Mepolizumab, CALY-002, BT-11, Barzolvolimab,  NDX33-o, SP16, Qi-201, Esomeprazole ODT, IRL201104, and others.

 

Request a sample and discover the recent advances in Eosinophilic esophagitis treatment @ Eosinophilic Esophagitis Pipeline Outlook

 

The Eosinophilic esophagitis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Eosinophilic esophagitis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Eosinophilic esophagitis pipeline landscape.

 

Eosinophilic Esophagitis Overview

Eosinophilic esophagitis is a chronic, immune-mediated/allergen-mediated clinicopathological disease. Clinically, it is distinguished by signs of esophageal dysfunction. EoE’s chronic inflammation causes Eosinophilic esophagitis symptoms. However, the exact Eosinophilic esophagitis causes are not known.

Early detection and Eosinophilic esophagitis treatment are critical to preventing the progression of fibrotic abnormalities in the esophagus, which may be only partially reversible. For Eosinophilic esophagitis diagnosis, an upper endoscopy including biopsies of the esophagus is required. Currently, Eosinophilic esophagitis treatment includes dietary elimination diets, off-label usage of proton pump inhibitors, and glucocorticoid steroid formulations.

 

Learn more about the novel and emerging Eosinophilic esophagitis pipeline therapies @ Eosinophilic Esophagitis Clinical Trials

 

Eosinophilic Esophagitis Therapeutics Assessment

The Eosinophilic esophagitis pipeline report proffers an integral view of the Eosinophilic esophagitis emerging novel therapies segmented by stage, product type,  molecule type,  mechanism of action, and route of administration.

 

Scope of the Eosinophilic Esophagitis Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
  • Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: Glucocorticoid receptor agonists, Interleukin 13 inhibitors, Interleukin 15 inhibitors, Antibody-dependent cell cytotoxicity, Apoptosis stimulants, Immunomodulators, Mast cell inhibitors, Immunomodulators, Proto oncogene protein c-kit inhibitors
  • Key Eosinophilic Esophagitis Companies: Sanofi/Regeneron, AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, DBV Technologies, Celldex Therapeutics, NexEos Bio, Aqilion,  Quorum Innovations, Serpin Pharma, RAPT Therapeutics, and others
  • Key Eosinophilic Esophagitis Pipeline Therapies: Dupilumab, Benralizumab, CC-93538, APT-1011, AK002, ESO-101, Etrasimod, Mepolizumab, CALY-002, BT-11, Barzolvolimab,  NDX33-o, SP16, Qi-201, Esomeprazole ODT, IRL201104, and others.

 

Dive deep into rich insights for drugs for Eosinophilic esophagitis, visit @ New Drug for Eosinophilic Esophagitis Treatment

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Eosinophilic Esophagitis: Overview
  4. Pipeline Therapeutics
  5. Comparative Analysis
  6. Therapeutic Assessment
  7. Eosinophilic Esophagitis – DelveInsight’s Analytical Perspective
  8. In-depth Commercial Assessment
  9. Eosinophilic Esophagitis Collaboration Deals
  10. Late Stage Products (Phase III)
  11. Comparative Analysis
  12. TAK721: Takeda
  13. Mid Stage Products (Phase II/III)
  14. AK002: Allakos
  15. Early stage products (Phase I)
  16. CALY 002 : Calypso Biotech
  17. Inactive Products
  18. Eosinophilic Esophagitis Key Companies
  19. Eosinophilic Esophagitis Key Products
  20. Eosinophilic Esophagitis- Unmet Needs
  21. Eosinophilic Esophagitis- Market Drivers and Barriers
  22. Eosinophilic Esophagitis- Future Perspectives and Conclusion
  23. Eosinophilic Esophagitis Analyst Views
  24. Eosinophilic Esophagitis Key Companies
  25. Appendix

 

For further information on the Eosinophilic esophagitis pipeline therapeutics, reach out @ Drugs for Eosinophilic Esophagitis

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/